Fast VT Episodes Are Terminated by ATP One Shot

NCT ID: NCT00617578

Last Updated: 2013-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

194 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many arrhythmias detected in the ventricular fibrillation (VF)-zone picture monomorphic ventricular tachycardia (VT) and, hence, could be terminated by antitachycardia pacing (ATP) treatment. Advantages of successful ATP are the painlessness termination and the shortened duration of arrhythmia. The ATP One Shot algorithm is integrated in the latest family of implantable cardioverter defibrillators (ICDs) from BIOTRONIK (Lumax). It allows a single delivery of ATP before charging capacitors to terminate lethal arrhythmia by painful shock.

The present study evaluates the efficacy of the ATP One Shot algorithm for the termination of fast VT episodes. 200 patients with secondary prophylactic ICD indication will be followed for 18 months. Spontaneous episodes detected in the VF-zone of the ICD will be evaluated with regard to cycle length, episode duration and course of device therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ICDs provide different detection zones for the therapy of VT and VF. An established form of therapy in the VT-zone is antitachycardia pacing (ATP). It is an effective, safe and painless method to terminate episodes of slow VT with a cycle length \> 300 ms. Episodes detected in the VF zone will result in the delivery of a high-energy shock to terminate life-threatening VF. Many arrhythmia detected in the VF-zone picture monomorphic VT and could be easily terminated by ATP. Advantages of a successful termination by ATP therapy would be the painlessness and the shortened duration of the episode, as there would be no need to load shock capacitors. Fast VT are often hemodynamically poorly tolerated by the patient and should be terminated within very short time. The ATP One Shot algorithm is integrated in the latest family of ICDs from BIOTRONIK (Lumax) to allow a single delivery of ATP before charging capacitors.

The main objective of the study is the assessment of the efficacy of the ATP One Shot algorithm for the termination of fast VT episodes. To this end, spontaneous episodes detected in the VF-zone of the ICD are evaluated with regard to cycle length, episode duration and course of device therapy. In the context of the study, a confirmatory (hypothesis-testing) primary problem is investigated. The goal is to measure the time to first adequate shock therapy for episodes detected in the VF-zone of the device and to analyze the hazard ratio of the standard ICD setting compared to a therapy with the ATP One Shot algorithm.

The clinical project is conducted as randomized prospective multicenter study. The chronological order and the scope of the follow-ups meet the medical standard according to the international guidelines. A center-based, stratified block randomization will be performed. In approximately 50% of the patients the ATP One Shot algorithm will be activated, while the other 50% will be randomized into the control group.

A total of about 20 European investigational sites will participate in the study. Each center should enroll about 10 patients who will be followed for 18 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventricular Tachycardia, Monomorphic

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Antitachy pacing Implantable cardioverter-defibrillator

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

programming of VF therapy: ATP (antitachycardia pacing) One Shot ON

Group Type EXPERIMENTAL

ATP One Shot ON

Intervention Type DEVICE

The new antitachycardia pacing algorithm "ATP One Shot" attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery

2

programming of VF therapy: ATP (antitachycardia pacing) One Shot OFF

Group Type ACTIVE_COMPARATOR

ATP One Shot OFF

Intervention Type DEVICE

Standard defibrillation shock delivery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ATP One Shot ON

The new antitachycardia pacing algorithm "ATP One Shot" attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery

Intervention Type DEVICE

ATP One Shot OFF

Standard defibrillation shock delivery

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ICD indication for reason of survived cardiac arrest, ventricular tachycardia or syncope

Exclusion Criteria

* ICD indication for reason of non-sustained VT post MI, positive family history for SCD (Brugada-, long/short QT-Syndrome), hypertrophic cardiomyopathy, primary prophylactic indication (e.g. SCD-HeFT, Madit II)
* Patients not capable of participating in the follow-ups
* Minors and pregnant women
* Patients who are already enrolled in another study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biotronik SE & Co. KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jörg Otto Schwab, PD Dr.

Role: STUDY_CHAIR

University Hospital Bonn, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medizinische Abteilung, LKH Bruck

Bruck / Mur, , Austria

Site Status

Innere Medizin - Kardiologie, Universitätsklinik Innsbruck

Innsbruck, , Austria

Site Status

Med. Abteilung, AKH Linz

Linz, , Austria

Site Status

Cardiology, Satakunta Central Hospital

Pori, , Finland

Site Status

Klinik für Innere Medizin, Vivantes Humboldt Klinikum

Berlin, , Germany

Site Status

Medizinische Klinik II, Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Medizinische Klinik I, Ev. Krankenhaus

Holzminden, , Germany

Site Status

Medizinische Klinik, Kreiskrankenhaus

Neustadt / Aisch, , Germany

Site Status

Kardiologie, DRK Krankenhaus Mölln

Ratzeburg, , Germany

Site Status

Kardiologische Praxis Dr. Placke

Rostock, , Germany

Site Status

Innere Medizin - Kardiologie, Klinikum Uckermark

Schwedt, , Germany

Site Status

Kliniken Villingen Schwenningen, Klinik für Innere Medizin III, Kardiologie

Villingen, , Germany

Site Status

Medizinische Klinik I, St-Josefs-Hospital

Wiesbaden, , Germany

Site Status

Cardiology, Rabin MC

Petah Tikva, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark Austria Finland Germany Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TA080

Identifier Type: -

Identifier Source: org_study_id